SYK
NEUTRAL
$329.69
Live
Stryker Corporation · NYSE
Target $425.08
(+28.9%)
$319.32
52W Range
$404.87
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 01, 2026
Market cap
$126.27B
P/E
39.2
ROE
15.1%
Profit margin
12.9%
Debt/Equity
0.73
Dividend yield
1.07%
AI Analysis
AI-powered fundamental assessment
Confidence
80%
SYK shows neutral fundamentals based on deterministic rules. Financial strength is strong (F-Score 7/9). Mixed signals with both opportunities and risks present.
Key Strengths
Strong financial trend (Piotroski F-Score: 7/9)
Strong ROE of 15.1%
Key Risks
High valuation with P/E of 39.2
Premium vs Graham Number ($105.31)
AI Fair Value Estimate
Based on comprehensive analysis
$248.09
-24.8% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
51
Moderate
35
50
60
70
40
AI Verdict
SYK shows neutral fundamentals based on deterministic rules. Financial strength is strong (F-Score 7/9). Mixed signals with both opportunities and risks present.
Key drivers: Strong financial trend (Piotroski F-Score: 7/9), Strong ROE of 15.1%, High valuation with P/E of 39.2
Confidence
60%
Value
35/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
- Premium 39.2x trailing earnings multiple.
- Trades above Graham Number.
Future
50/100
Rule-based growth outlook.
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Past
60/100
Historical performance + price trend: Shares moved +42.9% over 5Y and -10.8% over 1Y.
Positives
- ROE sits at 15.1%.
Watchpoints
No urgent risks highlighted.
Health
70/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Dividend
40/100
Dividend policy fallback.
Positives
- Moderate dividend profile (Score: 40/100).
- Yield: 1.1%.
Watchpoints
No urgent risks highlighted.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$329.69
Analyst Target
$425.08
Upside/Downside
+28.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SYK and closest competitors.
Updated 2026-04-01
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SYK
Stryker Corporation
Primary
|
+42.9% | +18.0% | -10.8% | -9.0% | -14.6% | +0.9% |
|
DHR
Danaher Corporation
Peer
|
-7.7% | -11.3% | +6.4% | -5.9% | +3.5% | -0.2% |
|
VRTX
Vertex Pharmaceuticals Incorporated
Peer
|
+109.6% | +41.7% | -7.9% | +14.0% | -8.1% | -0.5% |
|
BMY
Bristol-Myers Squibb Company
Peer
|
+2.8% | -13.4% | -2.9% | +15.8% | +1.1% | -1.1% |
|
GSK
GSK plc
Peer
|
+77.5% | +69.5% | +48.1% | +25.9% | +0.7% | -5.5% |
SYK
Stryker Corporation
Primary
5Y
+42.9%
3Y
+18.0%
1Y
-10.8%
6M
-9.0%
1M
-14.6%
1W
+0.9%
DHR
Danaher Corporation
Peer
5Y
-7.7%
3Y
-11.3%
1Y
+6.4%
6M
-5.9%
1M
+3.5%
1W
-0.2%
VRT
Vertex Pharmaceuticals Incorporated
Peer
5Y
+109.6%
3Y
+41.7%
1Y
-7.9%
6M
+14.0%
1M
-8.1%
1W
-0.5%
BMY
Bristol-Myers Squibb Company
Peer
5Y
+2.8%
3Y
-13.4%
1Y
-2.9%
6M
+15.8%
1M
+1.1%
1W
-1.1%
GSK
GSK plc
Peer
5Y
+77.5%
3Y
+69.5%
1Y
+48.1%
6M
+25.9%
1M
+0.7%
1W
-5.5%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
39.2
Forward P/E
19.69
PEG Ratio
N/A
P/B Ratio
5.62
P/S Ratio
5.03
EV/Revenue
5.5
EV/EBITDA
19.86
Market Cap
$126.27B
Profitability
Profit margins and return metrics
Profit Margin
12.92%
Operating Margin
27.23%
Gross Margin
65.04%
ROE
15.08%
ROA
7.92%
Growth
Revenue and earnings growth rates
Revenue Growth
+11.4%
Earnings Growth
+55.9%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+55.5%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.73
Moderate
Current Ratio
1.89
Good
Quick Ratio
1.04
Good
Cash/Share
$10.71
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$7.2B
Gross Margin
64.5%
Op. Margin
25.3%
Net Margin
11.8%
Total Assets
$47.8B
Liabilities
$25.4B
Equity
$22.4B
Debt/Equity
1.13x
Operating CF
$2.1B
CapEx
$-0.3B
Free Cash Flow
$1.9B
FCF Yield
87%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-01-29
$4.47
+1.7% surprise
2025-10-30
$2.22
-13.2% surprise
2025-07-31
$3.13
+1.9% surprise
Healthcare Sector Comparison
Comparing SYK against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
39.2
This Stock
vs
75.44
Sector Avg
-48.0%
(Discount)
Return on Equity (ROE)
15.08%
This Stock
vs
-88.14%
Sector Avg
-117.1%
(Below Avg)
Profit Margin
12.92%
This Stock
vs
-16.28%
Sector Avg
-179.4%
(Weaker)
Debt to Equity
0.73
This Stock
vs
2.66
Sector Avg
-72.6%
(Less Debt)
Revenue Growth
11.4%
This Stock
vs
124.04%
Sector Avg
-90.8%
(Slower)
Current Ratio
1.89
This Stock
vs
4.47
Sector Avg
-57.7%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SYK
Stryker Corporation
|
NEUTRAL | $126.27B | 39.2 | 15.1% | 12.9% | $329.69 | |
|
DHR
Danaher Corporation
|
NEUTRAL | $138.36B | 38.94 | 7.1% | 14.7% | $195.5 | Compare |
|
VRTX
Vertex Pharmaceuticals Incorporated
|
NEUTRAL | $113.44B | 28.9 | 22.5% | 32.9% | $446.54 | Compare |
|
BMY
Bristol-Myers Squibb Company
|
NEUTRAL | $111.25B | 18.46 | 33.8% | 12.6% | $54.65 | Compare |
|
GSK
GSK plc
|
BULLISH | $108.22B | 14.42 | 43.3% | 17.5% | $54.22 | Compare |
SYK
Stryker Corporation
NEUTRAL
Mkt Cap
$126.3B
P/E
39.2
ROE
15.1%
Price
$329.69
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-20 | MENON VIJU S | Officer | Stock Award | 269 | - |
| 2026-03-20 | FLETCHER ROBERT S | Officer | Stock Award | 225 | - |
| 2026-03-20 | PIERCE JAMES ANDREW | Officer | Stock Award | 430 | - |
| 2026-03-20 | LOBO KEVIN A | Chief Executive Officer | Stock Award | 1,452 | - |
| 2026-03-20 | STILES SPENCER S | President | Stock Award | 430 | - |
| 2026-03-20 | FINK MARY KATHRYN | Officer | Stock Award | 150 | - |
| 2026-03-09 | LOBO KEVIN A | Chief Executive Officer | Stock Award | 50,332 | - |
| 2026-03-09 | FINK MARY KATHRYN | Officer | Stock Award | 5,220 | - |
| 2026-03-09 | MENON VIJU S | Officer | Stock Award | 9,320 | - |
| 2026-03-09 | FLETCHER ROBERT S | Officer | Stock Award | 7,828 | - |
| 2026-03-09 | PIERCE JAMES ANDREW | Officer | Stock Award | 14,912 | - |
| 2026-03-09 | STILES SPENCER S | President | Stock Award | 14,912 | - |
| 2026-02-23 | STRYKER RONDA E | Director | Gift | 55,600 | - |
| 2026-02-17 | STRYKER RONDA E | Director | Gift | 600,200 | - |
| 2026-02-06 | LOBO KEVIN A | Chief Executive Officer | Option Exercise | 206,955 | $20,000,131 |
MENON VIJU S
Officer
2026-03-20
269 shares
FLETCHER ROBERT S
Officer
2026-03-20
225 shares
PIERCE JAMES ANDREW
Officer
2026-03-20
430 shares
LOBO KEVIN A
Chief Executive Officer
2026-03-20
1,452 shares
STILES SPENCER S
President
2026-03-20
430 shares
FINK MARY KATHRYN
Officer
2026-03-20
150 shares
LOBO KEVIN A
Chief Executive Officer
2026-03-09
50,332 shares
FINK MARY KATHRYN
Officer
2026-03-09
5,220 shares
MENON VIJU S
Officer
2026-03-09
9,320 shares
FLETCHER ROBERT S
Officer
2026-03-09
7,828 shares
PIERCE JAMES ANDREW
Officer
2026-03-09
14,912 shares
STILES SPENCER S
President
2026-03-09
14,912 shares
STRYKER RONDA E
Director
2026-02-23
55,600 shares
STRYKER RONDA E
Director
2026-02-17
600,200 shares
LOBO KEVIN A
Chief Executive Officer
2026-02-06
206,955 shares
·
$20,000,131
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
26 analysts
UBS
2026-03-17
Neutral
Neutral
UBS
2026-02-24
Neutral
Neutral
Needham
2026-01-30
Buy
Buy
BTIG
2026-01-30
Buy
Buy
Bernstein
2026-01-09
Outperform
Outperform
Citizens
2025-12-19
Market Perform
Market Outperform
Truist Securities
2025-12-18
Hold
Hold
Citigroup
2025-12-11
Buy
Buy
Truist Securities
2025-11-14
Hold
Hold
Wells Fargo
2025-11-14
Overweight
Overweight
Past News Coverage
Recent headlines mentioning SYK from our newsroom.
Newest → oldest
No matching news yet.